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Abstract
DNA methylation plays an important role in carcinogenesis and the reversibility of this epigenetic modification makes it a
potential therapeutic target. To date, DNA methyltransferase inhibitors (DNMTi) have not demonstrated clinical efficacy in
prostate cancer, with one of the major obstacles being the inability to monitor drug activity during the trial. Given the high
frequency and specificity of GSTP1 DNA methylation in prostate cancer, we investigated whether GSTP1 is a useful marker of
DNMTi treatment efficacy. LNCaP prostate cancer cells were treated with 5-aza-29-deoxycytidine (5-aza-CdR) either with a
single high dose (5–20 mM), every alternate day (0.1–10 mM) or daily (0.005–2.5 mM). A daily treatment regimen with 5-aza-
CdR was optimal, with significant suppression of cell proliferation achieved with doses of 0.05 mM or greater (p,0.0001) and
induction of cell death from 0.5 mM( p ,0.0001). In contrast, treatment with a single high dose of 20 mM 5-aza-CdR inhibited
cell proliferation but was not able to induce cell death. Demethylation of GSTP1 was observed with doses of 5-aza-CdR that
induced significant suppression of cell proliferation ($0.05 mM). Re-expression of the GSTP1 protein was observed only at
doses of 5-aza-CdR ($0.5 mM) associated with induction of cell death. Treatment of LNCaP cells with a more stable DNMTi,
Zebularine required at least a 100-fold higher dose ($50 mM) to inhibit proliferation and was less potent in inducing cell
death, which corresponded to a lack of GSTP1 protein re-expression. We have shown that GSTP1 DNA methylation and
protein expression status is correlated with DNMTi treatment response in prostate cancer cells. Since GSTP1 is methylated in
nearly all prostate cancers, our results warrant its testing as a marker of epigenetic therapy response in future clinical trials.
We conclude that the DNA methylation and protein expression status of GSTP1 are good indicators of DNMTi efficacy.
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Introduction
Prostate cancer is one of the most commonly diagnosed male
cancers in Western countries. Current therapies for clinically
localized disease include surgical removal of the prostate gland
(prostatectomy) and/or radiotherapy with or without androgen
deprivation therapy (ADT). Since the discovery, in the 1940s, that
prostate cancer is dependent on the male sex hormones [1],
initially castration and subsequently various forms of ADT, either
alone or combined with androgen receptor (AR) antagonists, have
been the main therapy for metastatic disease. After an initial
variable duration of tumor regression, most metastatic prostate
cancers progress to a ‘‘castration-resistant’’ stage that is unrespon-
sive to ADT. Currently there are limited treatment options
available for castration-resistant prostate cancer and consequently
there is a serious need to develop new therapies.
It is well-established that epigenetic alterations are common
events in carcinogenesis, including prostate cancer, which may
lead to aberrant expression of critical genes such as tumor
suppressors and oncogenes. Unlike DNA mutations, epigenetic
alterations are chemically reversible by agents known as epigenetic
inhibitors and are therefore potential therapeutic targets. Exam-
ples of epigenetic inhibitors that have shown success as therapeutic
agents include the DNA methyltransferase inhibitors (DNMTi), 5-
aza-cytidine (5-aza-CR or Vidaza) and its more potent analogue 5-
aza-29-deoxycytidine (5-aza-CdR or Decitabine). 5-aza-CR and 5-
aza-CdR are nucleoside DNMTi developed initially as cancer
chemotherapeutic agents that are currently being used for the
treatment of myelodysplastic syndromes (MDS) [2]. The demeth-
ylating actions of 5-aza-CR and 5-aza-CdR rely on their ability to
incorporate into replicating DNA and covalently bind to the
DNMT1 enzyme in an irreversible manner, which leads to
DNMT1 protein degradation [2,3]. As DNMT1 is required to
maintain DNA methylation during replication, the degradation of
DNMT1 subsequently results in a loss of DNA methylation.
Aberrant expression of epigenetic modifying enzymes involved
in the regulation of DNA methylation has been observed at all
stages of prostate cancer progression [4,5,6]. Global levels of 5-
methylcytosine and epigenetic modifying enzymes involved in
DNA methylation (i.e DNMTs) predict the likelihood of disease
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25634progression in prostate cancer. This finding suggests that DNA
methylation may be important in progression of prostate cancer
and therefore DNMTi should be considered as a potential
treatment option [7,8,9]. While in vitro experiments and animal
models have shown that 5-aza-CdR has anti-tumor activities in
several cancers including prostate cancer [10,11,12,13,14], clinical
trials of 5-aza-CdR for the treatment of solid tumors have not been
successful due to drug related adverse events such as myelosup-
pression, nausea and vomiting [15,16,17]. In addition to toxicity
issues, the efficiency of delivery and uptake of 5-aza-CdR to the
tumor tissues, there is uncertainty about the optimal dose-schedule
for specific tumor types [18]. To date, only one small phase II
study with 5-aza-CdR in prostate cancer has been published,
approximately a decade ago [16]. While there are ongoing clinical
trials for 5-aza-CdR in various solid tumors, none of these trials
are cancer-specific nor do they include prostate cancer (National
Institutes of Health, US, clinicaltrials.gov). In vitro studies
investigating the effects of 5-aza-CdR in prostate cancer cell lines
(see Table S1) have used various treatment regimes and different
definitions for low and high 5-aza-CdR doses, making it difficult to
compare between studies and define the optimal treatment regime,
including dose-schedule, for prostate cancer. Surprisingly, very few
of the in vitro studies (Table S1A) have investigated the effects of 5-
aza-CdR on the proliferation and survival of prostate cancer cells,
but rather have investigated the effect of 5-aza-CdR on gene
expression in order to identify candidate epigenetically-regulated
genes (Table S1B).
The aim of this study was to investigate the dose-dependent
effects of 5-aza-CdR in prostate cancer cells with view to providing
a basis for developing an optimal 5-aza-CdR treatment regime for
prostate cancer. We also investigated the relative toxicity of 5-aza-
CdR and Zebularine in LNCaP prostate cancer cells. Zebularine is
a cytidine analogue that has similar functions to 5-aza-CdR as a
demethylating agent, but is less toxic and has a more stable half life
(,508 hours at 37uC, pH 7) than 5-aza-CdR (12 hours at 37uC,
pH 7) [19,20]. Identification of a good marker of DNMTi efficacy
for clinical trials, much like the measurement of serum PSA levels
to monitor the efficacy of ADT [21], would have the potential to
aid clinical management of prostate cancer patients treated with
epigenetic therapies. To investigate the efficacy of 5-aza-CdR and
Zebularine in prostate cancer cells, we examined DNA methyl-
ation and expression status of the glutathione-S-transferase P1
(GSTP1) gene. GSTP1 is hypermethylated in nearly all human
prostate cancers and its promoter DNA methylation level is able to
differentiate between benign prostatic hyperplasia and different
grades of prostate adenocarcinoma [6,22,23,24,25]. While current
studies have focused on using GSTP1 as a potential marker for the
early detection of prostate cancer, we propose that assessing DNA
methylation of the GSTP1 promoter region, as well as expression
of GSTP1, has the potential to be a useful tool for determining
DNMTi efficacy in prostate cancer.
Materials and Methods
Measurement of cell viability
LNCaP and PC3 human prostate carcinoma cells (American
Type Culture Collection, ATCC) were maintained in RPMI 1640
supplemented with 5% or 10% fetal bovine serum (FBS). 5-aza-
CdR and Zebularine (Sigma, A3656 and Z4775) were dissolved in
dimethylsulfoxide (DMSO) and Hank’s buffered salt solution
respectively. For the single and every alternate day treatment with
5-aza-CdR, cells were seeded in triplicate in 24-well plates at a
density of 2.5610
4 cells per well in 1 mL of RPMI medium. For
the 5-aza-CdR daily treatment and Zebularine treatment, cells
were seeded in triplicate in 12-well plates at a density of
1610
4 cells per well in 1 mL of RPMI medium. Cells were
allowed to attach for 241h or 48 h, once cell confluency was
reached and then incubated with medium containing 5-aza-CdR
at concentrations of 0–20 mM or Zebularine at concentrations of
50–1000 mM. For subsequent or additional treatments, fresh 5-
aza-CdR or Zebularine diluted in media was added to the cells.
Media containing the respective agents were freshly prepared from
10 mM 5-aza-CdR and 70 mM Zebularine stocks before each
treatment. Cells were trypsinized and counted using a hemocy-
tometer at the specified time-points after initiation of treatment
and cell viability assessed by Trypan blue dye exclusion as
previously described [26]. Data are expressed as the mean +/2 SE
of triplicate wells and are representative of at least two
independent experiments.
Immunoblotting
LNCaP cells were seeded in 6-well plates at a density of
2610
4 cells per well in 2 mL of RPMI medium containing 10%
FBS. Cells were allowed to attach for 24 h before medium was
replaced with medium containing treatments. Cells were lysed by
adding radioimmunoprecipitation assay lysis buffer (10 mM Tris-
HCL, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100)
containing mini-complete protease inhibitor pellets (Roche).
Lysates (15–30 mg) were electrophoresed through 5% or 12%
polyacrylamide gels, transferred to nitrocellulose membrane
(Amersham Biosciences), and blocked in 5% non-fat milk powder
in TBS containing 0.05% Tween20 overnight. Immunodetection
was performed with the specific primary antibody diluted in 1%
non-fat milk powder in TBS containing 0.05% Tween20. GSTP1
antibody (Chemicon, AB8902) was used at a dilution of 1:5000
and overnight incubation at 4uC. Hsp90 antibody (Santa Cruz
Biotechnology) was used at a dilution of 1:1000 and 30 min
incubation at room temperature. Horseradish peroxidase-conju-
gated anti-rabbit secondary antibody (DAKO, E0432) was used at
a dilution of 1:2000 and 30 min incubation at room temperature.
Results were visualized on Hyperfilm (GE Healthcare) using
enhanced chemiluminescence detection (GE Healthcare).
DNA methylation analysis
After cell viability assessment, the remaining LNCaP cells were
collected for genomic DNA extraction using TES (10 mM Tris-
HCL at pH 8, 0.1 M NaCl, 1 mM EDTA) buffer, proteinase K
and 20% SDS as described previously [27]. DNA (1–2 mgp e r
sample) was bisulfite modified with the MethylEasy
TM DNA
Bisulphite Modification Kit (Human Genetic Signatures Pty Ltd)
according to the manufacturer’s protocol. A total volume of 25 ml
or 50 ml PCR reaction mix was made up with 3–5 ml of the
bisulfite modified DNA and 2.5 units of HotstarTaq DNA
polymerase (Qiagen). GSTP1 Methylation-Specific Polymerase
chain reaction (MSP) [28] and COmbined Bisulfite Restriction
Analysis (COBRA) [29] primers were purchased from Gene-
Works (South Australia, Australia). GSTP1 MSP primer sequenc-
es were as described previously [24] and all primer sequences
used in this study are provided in Figure S1. The annealing
temperatures for the respective primers were: 40 cycles at 64.3uC
for methylated GSTP1 MSP primers; 45 cycles at 61.6uCf o r
unmethylated GSTP1 MSP primers; 45 cycles at 56.8uCf o r
GSTP1 COBRA primers. PCR products from the GSTP1
COBRA analyzes were digested with restriction enzymes BstUI
and HhaI (New England BioLabs). PCR products were visualized
by agarose gel electropheresis with the AlphaImager 2200 gel
documentation system (San Leandro).
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One-way analysis of variance (ANOVA) with a post-hoc
Dunnet’s multiple comparison test was used to compare cell
viability between treatments and the vehicle control when a single
time-point was assessed. Two-way ANOVA with a post-hoc
Bonferroni test was used to compare cell viability between
treatments and the vehicle control when multiple time-points
were assessed. Analyses were performed with the GraphPad Prism
5 software (GraphPad Software, Inc., CA USA) and statistical
significance was set at p,0.05 (two-sided).
Results
Daily 5-aza-CdR treatment is required to induce optimal
inhibition of proliferation and induction of cell death in
LNCaP prostate cancer cells
To investigate the efficacy of different 5-aza-CdR treatment
schedules, we performed cell proliferation and viability assays on
LNCaP prostate cancer cells and compared the following: a single
treatment, alternate day treatments and daily treatments. When
compared to the control (vehicle), a single treatment of 5-aza-CdR
effectively suppressed LNCaP prostate cancer cell proliferation at
all concentrations used (5-20 mM) (Figure 1A, Day 4: p,0.001 for
5 mM and p,0.0001 for 10, 20 mM, Day 6: p,0.0001 for all
doses) but did not induce significant cell death 6 days after
treatment (Figure 1B). When 5-aza-CdR was added every second
day (alternate day treatment), lower doses of 5-aza-CdR (0.1, 0.5
and 2.5 mM) compared to doses used in the single treatment
schedule resulted in a significant dose-dependent inhibition of cell
proliferation when compared to vehicle treated LNCaP cells
(Figure 1C, Day 4 and 6: p,0.0001 for all doses). Only doses of 5-
aza-CdR of 2.5 mM or greater induced significant cell death when
compared to that of vehicle treated cells (Figure 1D, Day 6:
p,0.001 for 2.5 mM and p,0.0001 for 10 mM). In contrast, daily
treatment of 5-aza-CdR achieved significant inhibition of
proliferation at lower concentrations (0.05 mM) (Figure 2A, Day
6: p,0.05 for 0.05 mM, p,0.001 for all doses 0.5 mM or greater,
Day 8: p,0.05 for 0.01 mM and p,0.001 for all doses 0.05 mMo r
greater) and increased cell death in LNCaP cells (Figure 2B, Day
8: p,0.001 for doses 0.5 mM or greater) compared to similar doses
given every second day. Dose-dependent inhibition of proliferation
Figure 1. Single and alternate day 5-aza-CdR treatment of LNCaP prostate cancer cells. LNCaP prostate cancer cells (2.5610
4 cells per well
in 24-well plates) were treated with increasing doses of 5-aza-CdR (5–20 mM) administered (A–B) once on day 0 or (C–D) with increasing doses of 5-
aza-CdR (0.1-10 mM) replenished on alternate days for up to 6 days. (A) and (C) cells were counted at regular intervals using a hemocytometer and the
number of viable cells was assessed by Trypan blue dye exclusion. (B) and (D) the number of dead cells is expressed as a percentage of the total
number of cells counted. Data at each time-point represents the mean +/2 SE of triplicate wells. *Two-way ANOVA: p,0.0001 for (A), (C) and (D)
(10 mM); p,0.001 for (D) (2.5 mM) when compared to vehicle control (veh) on last day of treatment.
doi:10.1371/journal.pone.0025634.g001
GSTP1 and DNMTi Efficacy in Prostate Cancer
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e25634Figure 2. Daily 5-aza-CdR treatment of LNCaP and PC3 prostate cancer cells. (A–B) LNCaP and (C–D) PC3 prostate cancer cells (1610
4 cells
per well in 12-well plates) were treated with increasing doses of 5-aza-CdR (0.005–2.5 mM) replenished daily for up to 8 days. (A) and (C) cells were
counted at regular intervals using a hemocytometer and the number of viable cells was assessed by Trypan blue dye exclusion. (B) and (D) the
number of dead cells is expressed as a percentage of the total number of cells counted. (E) and (F) relative cell viability following 6 or 8 days of
treatment with 5-aza-CdR was presented as the percentage of viable cells compared to vehicle control (veh) and relative cell death as the fold of
GSTP1 and DNMTi Efficacy in Prostate Cancer
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resulting in a 62% reduction in cell number when compared to
vehicle treated cells and complete inhibition of proliferation at
doses of 0.5 mM or greater (Figure 2A and 2E, p,0.0001). At the
doses that caused complete inhibition of proliferation, there was
also a significant increase in cell death, of approximately 3-fold,
when compared to vehicle control (Figure 2B and 2F, p,0.0001).
Effects of 5-aza-CdR on prostate cancer cell viability is
independent of the AR
To determine if the effects of 5-aza-CdR in LNCaP cells were
dependent on a functional AR, a daily treatment schedule, was also
performed in PC3 cells, which lack a functional AR. When treated
with 5-aza-CdR at doses of 0.005–2.5 mM, there was a similar dose-
dependent inhibition of proliferation and induction of cell death in
PC3 cells as there was in LNCaP cells (Figure 2A–D). Whereas an
approximate 3-fold induction of cell death was seen with 0.5 mM5 -
aza-CdR in both cell lines (Figure 2F), in the PC3 cells, lower doses
of 5-aza-CdR (0.005 mM and 0.01 mM) resulted in a significant
reduction in cell number (p,0.0001, Figure 2E), and this occurred
at an earlier time-point (4 days) when compared to LNCaP cells (6
days) treated identically (Figure 2A and 2C). Since 5-aza-CdR relies
on dividing cells for incorporation to elicit its effects, the difference
in doubling time between the 2 cell lines, approximately 24 hours in
PC3cellscomparedto48hoursintheLNCaPcells,mayexplainthe
increased potency of 5-aza-CdR on PC3 cell viability. The
androgen-independent inhibition of proliferation and induction of
cell death by 5-aza-CdR in prostate cancer cells was further
confirmedbycellviabilityassaysperformed inLNCaPcellscultured
in steroid-depleted medium (Figure S2).
Prolonged 5-aza-CdR treatment results in similar cell
death regardless of the treatment regime
To further characterize the differences between the alternate day
and daily treatment regime, the highest alternate day treatment
(10 mM) and the highestdaily treatment (2.5 mM) were compared in
an extended growth curve (Figure 3). LNCaP prostate cancer cells
were treated with vehicle control or 5-aza-CdR replenished on
alternate days or daily, as above. Cell viability and cell death were
assessed after 6 days of treatment. One set of cells then continued to
receive 5-aza-CdR replenished on alternate days or daily until day
12 (denoted as 10 mM-12d or 2.5 mM-12d; Figure 3) while the other
set of cells received media containing vehicle control (denoted as
10 mM-6d or 2.5 mM-6d; Figure 3). After 6 days of treatment, both
the alternate day and daily treatment regimes induced growth
suppression compared with vehicle control but only the daily
treatment resulted in cell death (Figure 3). As the control cells had
reached confluency by day 6, these cells were excluded for the
remainder of the experiment. With continued treatment on either
regime the amount of cell death continued to increase for the 12
days, reaching 61.4% for the alternate day treatment and 68.6% for
the daily treatment. Interestingly, the cells that only received
treatment for 6 days displayedequivalent levels of cell death to those
that received treatment for 12 days (Figure 3).
GSTP1 promoter DNA methylation status and protein re-
expression as markers of 5-aza-CdR efficacy
To investigate how the anti-proliferative effects of 5-aza-CdR
relate to its demethylating activity, MSP was performed to assess
the DNA methylation status of the GSTP1 promoter (Figure 4A).
Hypermethylated GSTP1 promoter DNA was present in LNCaP
cells treated with vehicle control. In contrast, unmethylated GSTP1
promoter DNA was detected in LNCaP cells treated daily with
0.05 mM or greater 5-aza-CdR, but completely demethylated
GSTP1 promoter DNA was not observed with even the highest
concentration of 5-aza-CdR. Demethylation of the GSTP1
promoter by 5-aza-CdR at doses great than or equal to
0.05 mM coincided with the ability of 5-aza-CdR to substantially
inhibit cell proliferation at these concentrations (Figure 2A-B).
To further examine the relative DNA methylation status of the
GSTP1 promoter in the 5-aza-CdR treated LNCaP cells, COBRA
was performed using BstUI and HhaI restriction enzymes
(Figure 4B–C). The unmethylated GSTP1 promoter present in
MDA-MB-231 breast cancer cells was not digested by BstUI or
HhaI (Figure 4B). Consistent with the MSP results, methylated
GSTP1 promoter was detected in vehicle treated (control) and 5-
aza-CdR treated LNCaP cells at doses of 0.005–0.5 mM.
Considerable GSTP1 promoter DNA demethylation was only
seen in response to 0.5 mM 5-aza-CdR, which is the lowest 5-aza-
CdR dose sufficient to induce complete inhibition of LNCaP cell
proliferation and cell death demonstrated in the cell viability
assays (Figure 2A–B). These findings suggest that the efficacy of
0.5 mM 5-aza-CdR is due to its ability to induce greater DNA
demethylation of GSTP1 compared to lower doses.
The greater demethylating effect of 0.5 mM compared to
0.05 mM 5-aza-CdR corresponds with GSTP1 protein re-expres-
sion observed at 0.5 mM 5-aza-CdR or greater (Figure 4D).
Consistent with this, the 5-aza-CdR doses that result in re-
expression of GSTP1 protein also induce significant cell death in
LNCaP cells (Figure 2B and 2F).
Zebularine inhibits proliferation of prostate cancer cells
but has limited effects on cell death
LNCaP cells were treated with Zebularine (0–1000 mM; highest
dose used in previous studies [30]), while PC3 cells were treated
with Zebularine doses of up to 400 mM. Zebularine was given on
day 0 and replenished again halfway through the treatment
period. Zebularine caused a dose-dependent inhibition of
proliferation in both LNCaP and PC3 prostate cancer cells
(Figure 5A and 5C, p,0.0001), suggesting that Zebularine has a
similar AR-independent growth inhibitory mechanism of action
on prostate cancer cells as 5-aza-CdR. A significant reduction in
the number of viable cells was observed with 100 to 200 mM
Zebularine, and complete inhibition of cell proliferation was
observed at 400 mM or greater in both LNCaP and PC3 cells
(Figure 5A and 5C, p,0.0001). Whereas Zebularine failed to
induce cell death at any dose in LNCaP cells (Figure 5B),
significant cell death was induced by 400 mM Zebularine in PC3
cells (Figure 5D, p=0.0004).
Zebularine has weaker demethylating actions on the
GSTP1 promoter compared to 5-aza-CdR
To investigate the demethylating activity of Zebularine, MSP
was performed to examine the DNA methylation status of the
GSTP1 promoter in LNCaP cells (Figure 6A). After 8 days of
treatment, methylated GSTP1 was present in the vehicle control
and all Zebularine treated samples (0–400 mM), while demethyl-
ation of the GSTP1 promoter lacked dose-dependency (Figure 6A).
percent of dead cells compared to the veh control. Data at each time-point represents the mean +/2 SE of triplicate wells from at least two
experiments. *Two-way ANOVA: p,0.05 for (A) (0.01 mM); p,0.001 for (A) (0.05–2.5 mM), (B) and (D) (0.5 mM); p,0.0001 for (C) and (D) (1, 2.5 mM)
when compared to vehicle control (veh) on last day of treatment.
doi:10.1371/journal.pone.0025634.g002
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region in these Zebularine-treated LNCaP cells were compared by
COBRA using BstUI and HhaI restriction enzyme digestion, no
unmethylated GSTP1 was detected (Figure 6B). The weak and
inconsistent demethylating actions of Zebularine on LNCaP cells
was also reflected in the lack of GSTP1 protein re-expression after
8 days of treatment (Figure 6C).
Discussion
While the DNMTi 5-aza-CdR is effective in the treatment of
hematologic conditions, clinical trials in solid tumors and in
prostate cancer have shown limited or no efficacy. The failure of
previous clinical trials in solid tumors has been attributed to
inappropriate dose regimens, leading to toxicity-related adverse
events. In part, this is due to a poor understanding of the
mechanistic actions of 5-aza-CdR in solid tumors. In this study, we
demonstrate that 5-aza-CdR, at a dose of 0.5 mM given daily,
completely inhibited cell proliferation and induced cell death in
prostate cancer cells, and was associated with demethylation of the
GSTP1 promoter and re-expression of GSTP1 protein. These
findings suggest that a daily low-dose 5-aza-CdR treatment
regimen may be more effective than a less frequent or single
high-dose schedule for the control of prostate cancer cell growth.
We have also demonstrated that a daily low-dose 5–aza-CdR
treatment regimen is more effective than one using the more stable
DNMTi, Zebularine. Most importantly, we provide evidence that
the increased potency of 5-aza-CdR compared to Zebularine in
prostate cancer cells is closely related to its demethylating activity
and identified GSTP1 as a potentially useful biomarker for
assessing DNMTi efficacy in prostate cancer.
Several studies have demonstrated that 5-aza-CdR reduces cell
proliferation and induces re-expression of specific genes in various
cancers (Table S1). Different cancer types respond to 5-aza-CdR
differently, but a wide range of 5-aza-CdR doses and treatment
regimens have been used in previous studies, and the end-points
Figure 3. Prolonged alternate day or daily treatment with 5-aza-CdR in LNCaP cells results in similar cell death. (A) and (C) LNCaP
prostate cancer cells (2.5610
4 cells per well in 24-well plates) were treated with 10 mM 5-aza-CdR or vehicle control, replenished on alternate days. (B)
and (D) LNCaP prostate cancer cells (1610
4 cells per well in 12-well plates) were treated with 2.5 mM 5-aza-CdR or vehicle control, replenished daily.
Following 6 days of treatment, control cells were ceased and the remaining cells either continued to receive 5-aza-CdR (10 mM-12d or 2.5 mM-12d,
respectively) or received fresh media containing vehicle (10 mM-6d or 2.5 mM-6d). (A) and (C) cells were counted at day 6, 8 and 12 using a
hemocytometer and the number of viable cells was assessed by Trypan blue dye exclusion. (B) and (D) the number of dead cells is expressed as a
percentage of the total number of cells counted.
doi:10.1371/journal.pone.0025634.g003
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studies have investigated the effects of 5-aza-CdR on the viability
of prostate cancer cell lines (Table S1A) [10,11,31,32,33,
34,35,36,37]. Comparisons among these studies are difficult due
to the reasons listed above. For instance, Walton et al [11]
reported approximately 30% inhibition of cell proliferation
compared to vehicle control in the LNCaP prostate cancer cells
after treatment with 8.8 mM 5-aza-CdR, while Pulukuri et al [10]
reported 70% inhibition of cell proliferation compared to vehicle
control in the same cell line with a high dose of 10 mM 5-aza-CdR
treatment. In contrast, our prolonged 5-aza-CdR daily treatment
regime resulted in approximately 62% inhibition of cell prolifer-
ation in LNCaP cells treated with 0.05 mM 5-aza-CdR, a dose
200-fold lower than what was used by Pulukuri et al [10] to
achieve a similar level of inhibition on cell proliferation.
Therefore, it would appear that administration of a low daily
dose of 5-aza-CdR is optimal for inhibition of prostate cancer cells
by this DNMTi.
In our one-time high dose 5-aza-CdR treatment of prostate
cancer cell lines, we chose a range of doses commonly used in
previous studies and found that while these doses of 5-aza-CdR
inhibited prostate cancer cell proliferation, they did not induce cell
death. This is consistent with the study by Walton et al, where 5-
aza-CdR failed to induce cytotoxicity in prostate cancer cell lines
even at a very high dose of 100 mM [11]. However, by increasing
the frequency of administration of 5-aza-CdR, we increased its
efficacy such that previously ineffective low doses of 5-aza-CdR
became sufficient to both inhibit cell proliferation and induce cell
death. As 5-aza-CdR is degraded within 12 hours [19,20,30], it is
not able to incorporate into replicating DNA to elicit its
demethylating actions in the single treatment regime. Replenish-
ment of 5-aza-CdR daily ensures that sufficient levels of the drug
are sustained throughout the treatment period to improve efficacy.
While previous studies have performed similar 5-aza-CdR daily
treatments in other cancer cell lines, the treatment period (3–4
days only) was relatively short and did not achieve the same
efficacy in terms of cell proliferation and cell death when
compared to the treatment regimen used in our study [38,39].
The rationale for a low dose daily 5-aza-CdR treatment regime
for prostate cancer in vitro is similar to that for the prolonged low
dose treatment used in hematological malignancies [40,41,42,43].
The initial development of 5-aza-CdR as an anti-leukemic agent
started when ‘pioneer’ studies demonstrated its efficacy in
leukemic cell lines and mouse models [44,45]. 5-aza-CdR was
able to influence leukemic cell differentiation and induce gene
expression that was associated with its DNA demethylating activity
[2]. This led to initial clinical trials with 5-aza-CdR in patients
with acute leukemia in the 1980s, branching later into clinical
trials with several hematopoietic malignancies including myelo-
dysplastic syndrome (MDS), sickle cell anemia and solid tumors
[15,46,47]. However, results of these trials were not promising and
were limited by poor pharmacokinetics, toxicity and an ineffective
dose schedule. It was not until the late 1990s when a prolonged
low dose schedule of 5-aza-CdR was introduced that promising
results were achieved in clinical trials for the treatment of
hematopoietic malignancies [40,41,42,43]. The new dose sched-
ule, based on an improved understanding of 5-aza-CdR
mechanisms, was crucial for the development of 5-aza-CdR as a
therapeutic agent. Other studies have shown that 5-aza-CdR is an
S-phase specific agent, and that low and high doses of 5-aza-CdR
have differential actions. Most importantly, low doses of 5-aza-
CdR were sufficient to induce demethylation and re-expression of
genes, without the cytotoxicity associated with higher doses
[48,49].
In addition to its demethylating activity, previous studies have
shown that 5-aza-CdR is involved in several signaling pathways
including cell cycle, DNA damage repair, apoptosis and
angiogenesis [50]. For instance, 5-aza-CdR anti-tumor activities
are p53-dependent [10,51]. Studies by both Pulukuri et al and
Karpf et al demonstrated that p53 positive cancer cell lines were
more sensitive to 5-aza-CdR compared to p53 negative cell lines
[10,51]. We, however, observed similar 5-aza-CdR responses in
the p53 positive LNCaP and p53 negative PC3 prostate cancer
cells lines, suggesting that p53 independent mechanisms were
Figure 4. GSTP1 DNA methylation and protein expression in
LNCaP cells after daily 5-aza-CdR treatment. DNA and proteins
were extracted from LNCaP cells treated with increasing doses of 5-aza-
CdR (0.005–2.5 mM). Cells were treated daily and DNA and protein
harvested after 6 days of treatment. (A) MSP was performed on
bisulfite-modified DNA with primers targeting bisulfite-modified
methylated GSTP1 promoter or unmethylated GSTP1 promoter. (B–C)
the relative methylation status of the GSTP1 promoter following 5-aza-
CdR treatment was further assessed by COBRA using two restriction
enzymes, BstUI and HhaI. MDA-MB-231 breast cancer cells were used as
a control for unmethylated GSTP1 promoter. (D) Immunoblot was
performed to analyze GSTP1 protein expression. Detection of Hsp90
was used as a loading control.
doi:10.1371/journal.pone.0025634.g004
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In this study, we also provide evidence that 5-aza-CdR does not
require expression of a functional AR to elicit its effects in prostate
cancer cells. The AR is critical for the maintenance of normal
prostate function and the development and progression of prostate
cancer, and is the main target in current treatments for prostate
cancer. 5-aza-CdR anti-tumor activities were similar in LNCaP
and PC3 cells, the latter lacking a functional AR. 5-aza-CdR
remained effective in reducing cell viability in LNCaP cells in the
absence of androgens, suggesting an androgen-independent
mechanism. These findings are supported by in vivo studies of 5-
aza-CdR in the TRAMP mouse model of prostate cancer [13,14].
Upon castration, the TRAMP mouse develops ‘‘castration-
resistant’’ prostate tumors similar to that seen with the recurrence
of human prostate tumor growth after androgen-deprivation
therapy. Treatment with 5-aza-CdR was found to increase
survival of TRAMP mice and delayed prostate cancer progression,
including the recurrence of prostate tumor growth after castration
[13,14]. Together, these results infer a potential role for epigenetic
therapies such as 5-aza-CdR in the treatment of prostate cancer
regardless of AR or androgen status.
While there remains controversy as to whether the anti-tumor
activity of 5-aza-CdR is due to its demethylating activity or
formation of DNA adducts [52,53] one hypothesis is that low doses
of 5-aza-CdR and high doses of 5-aza-CdR act via different
mechanisms to elicit their anti-tumor effects. A major finding in
this study is the correlation between 5-aza-CdR demethylation
activity with inhibition of cell proliferation and GSTP1 protein re-
expression and induction of cell death. Although past studies have
shown that 5-aza-CdR was able to demethylate and re-express
GSTP1 in prostate cancer cells [54,55,56], our results are the first
to demonstrate that GSTP1 methylation and protein status was
indicative of 5-aza-CdR treatment efficacy using a daily low-dose
Figure 5. Effects of Zebularine treatment on LNCaP and PC3 prostate cancer cell viability and cell death. (A-B) LNCaP and (C–D) PC3
prostate cancer cells (1610
4 cells per well in 12-well plates) were treated with increasing doses of Zebularine (0–400 mM, up to 1000 mM for LNCaP
cells) replenished once on day 4 for a period of 6 days for PC3 cells, and 8 days for LNCaP cells. (A) and (C) cells were counted at regular intervals using
a hemocytometer and cell viability was assessed by Trypan blue dye exclusion. (B) and (D) the number of dead cells is expressed as a percentage of
the total number of cells counted. Data at each time-point represents the mean +/2 SE of triplicate wells. *One-way ANOVA; p,0.0001 for (A) and (C);
p=0.0004 for (D) compared to vehicle control (veh).
doi:10.1371/journal.pone.0025634.g005
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differential mechanism between ‘‘low’’ (inhibition of cell prolifer-
ation only) and ‘‘high’’ (induction of cell death) doses of 5-aza-
CdR. Interestingly, the presence of GSTP1 protein itself does not
influence prostate cancer cell proliferation [54], yet its DNA
methylation and protein status seems to be indicative of the
efficacy of DNMTi treatment. Furthermore, the DNA methylation
and protein status of GSTP1 was indicative of the poor treatment
response with Zebularine. Even though Zebularine effectively
reduced prostate cancer cell number, it was unable to induce
significant cell death, possibly due to its weak demethylating
activity and inability to reactivate silenced genes such as GSTP1.
Although initial studies suggested that Zebularine may be a better
DNMTi than 5-aza-CdR for clinical use, this and other studies
suggest that Zebularine is not as effective as 5-aza-CdR as a
demethylating agent [39,57].
One of the obstacles in previous clinical trials with DNMTis such
as 5-aza-CdR, was the inability to investigate the efficacy of the drug
in patients until the conclusion of the trial. Based on the findings of
this study, we propose that GSTP1 is a marker of DNMTi treatment
efficacy in prostate cancer. The ability to track efficacy of the drug
using tissue biopsies or circulating tumor cells at earlier time-points
will greatly assist future clinical trials. Firstly, it has the potential to
improve the assessment of drug efficacy, thus reducing both the
duration and cost of a clinical trial, and secondly to improve the
welfare of patients in clinical trials by minimizing unnecessary
exposure. Another advantage of using GSTP1 as a marker of DNMTi
efficacy is that it can be easily measured in a patient’s serum [58] or
circulating tumor cells which will facilitate its use as a biomarker in
future clinical trials. GSTP1 status after neoadjuvant treatment with
DNMTi may also be a useful prognostic marker, similar to the
prognostic significance of Ki67 after neoadjuvant treatment with
endocrine and chemo-therapies in breast cancer [59,60].
Supporting Information
Figure S1 GSTP1 COBRA and MSP primers specific for
bisulfite modified unmethylated and methylated GSTP1.
The capital T defines thymines that are converted from cytosine
residues by bisulfite modification. Unmethylated CpGs become
TpG (Tg) and methylated CpGs (cg) remain unchanged upon
conversion. The GSTP1 COBRA primers were designed to target
both unmethylated and methylated GSTP1. Following PCR
amplification, PCR products were digested with either BstUI or
HhaI restriction enzymes. The restriction sites identified by BstUI
(CG_CG) are highlighted by bold lines while the restriction sites
for HhaI (C_CGC) are highlighted by dashed line. The GSTP1
MSP primers consist of one set of primers specific for unmethylated
GSTP1 and another set of primers specific for methylated GSTP1.
The start site of GSTP1 exon1 is indicated as +1.
(TIF)
Figure S2 5-aza-CdR daily treatment of LNCaP and PC3
cellsinsteroid-depletedcultureenvironment.(A–B)LNCaP
and (C–D) PC3 cells were cultured in steroid-depleted medium and
treated with increasing doses of 5-aza-CdR (0.005–2.5 mM)
replenished daily for a period of 8 or 6 days respectively. (A) and
(C) cells were counted at regular intervals using a hemocytometer
and cell viability was assessed by Trypan blue dye exclusion. (B) and
(D) the number of dead cells is expressed as a percentage of the total
number of cells counted. Data at each time-point represents the
mean +/2 SE of triplicate wells. *One-way ANOVA; p,0.0001 for
(A) and (C); p=0.007 for (D) compared to vehicle control (veh).
(TIF)
Table S1 Summary of studies investigating 5-aza-cyti-
dine (5-aza-CR) or 5-aza-29-deocycytidine (5-aza-CdR) in
prostate cancer cells.
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Figure 6. DNA methylation status and protein expression of
GSTP1 in LNCaP cells after Zebularine treatment. DNA and
proteins were extracted from LNCaP cells after 8 days of treatment with
increasing doses of Zebularine (0–400 mM). (A) DNA was bisulfite-
modified and MSP was performed with primers targeting bisulfite-
modified methylated GSTP1 or unmethylated GSTP1. (B) The relative
DNA methylation status of the GSTP1 promoter following Zebularine
treatment was assessed by COBRA using two restriction enzymes, BstUI
or HhaI. (C) Immunoblot was performed to analyse GSTP1 protein
expression in LNCaP cells after 8 days of Zebularine treatment. Proteins
were extracted from LNCaP cells treated with increasing doses of
Zebularine (0–400 mM). PC3 cells express endogenous GSTP1 protein
and were used as positive control.
doi:10.1371/journal.pone.0025634.g006
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